

25 August 2020

Consumer Non-cyclical | Packaging

Daibochi (DPP MK)

Not Rated

Unlocking Its Full Potential

Fair Value (Return):	MYR3.85 (+35%)
Price:	MYR2.85
Market Cap:	USD223m
Avg Daily Turnover (MYR/USD)	0.39m/0.09m

- MYR3.85 FV reflects an ascribed 20x P/E on 2021F EPS.** Daibochi's earnings hit a record high, benefiting from the integration of its processes with Scientex, which has resulted in lower variable and fixed costs. We expect a similar synergy from the MPP acquisition through increased capacity, wider customer network and reduced costs from pooling resources. In the longer term, with its strong MNC track record, better cost structure and continuous R&D, we expect it to record earnings CAGR of c.16% over FY20F-22F.
- Safe haven.** With 85% of revenue contributed by the food & beverage (F&B) sector, we expect Daibochi's revenue base to remain stable amidst market uncertainty. Having several multinational companies (MNCs), eg Nestle, PepsiCo, Mondelez International and Mars, in its client portfolio also provide stability in terms of product demand and margins. The supply business to MNCs tends to have higher barriers to entry due to the research & development (R&D) and relationship-building required before receiving sizable orders. As such, Daibochi is able to offer earnings visibility and a more stable growth trajectory – which should be appreciated by the market given the volatile market conditions.
- Hitting record earnings.** With the integration of its operations with Scientex (SCI MK, NEUTRAL, TP: MYR9.80), we are seeing some immediate results – Daibochi achieved record earnings with only nine months of core earnings in 9MFY20 of MYR37.6m – mainly driven by margin improvement. We expect the collaboration to continue to strengthen both companies' competitive advantage through combined technical expertise, product offerings and R&D over the longer term.
- Greater than the sum of its parts.** We expect the company's performance to further improve as it integrates Mega Printing & Packaging (MPP) (refer to page 6 for more details) into its operations. Apart from increasing capacity and widening customer network, the MPP acquisition should also create cost synergies from the pooling of resources, which effectively optimises raw material sourcing and other fixed costs. MPP, which focuses on local customers, will complement Daibochi's predominantly multinational clientele. Product-wise, Daibochi's main focus will be on complex packaging while MPP concentrates on simple packaging structures. Wider offerings and strong operating leverage will likely aid in scaling up.
- Well-positioned to further widen its reach.** In the longer term, we expect earnings to be driven by organic topline expansion and improved operating leverage as it ramps up production. With a strong track record with MNCs, more efficient cost structure and continuous R&D efforts, we believe the company will strive to secure new clients and new orders from existing clients. Daibochi recently shared that it will invest MYR60m in capacity expansion to support its long-term growth strategies. We expect it to record FY20F-22F earnings CAGR of c.16%.
- Key risks.** Margin erosion from intense competition, loss of major customers and steep increases in raw material prices.


Analyst

Muhammad Afif Bin Zulkaply
+603 9280 8883
muhammad.afif.zulkaply@rhbgroup.com



Share Performance (%)

	YTD	1m	3m	6m	12m
Absolute	26.1	1.4	17.3	17.8	64.7
Relative	27.4	2.7	8.1	12.5	67.2
52-wk Price low/high (MYR)	1.47 – 2.95				



Source: Bloomberg

Forecasts and Valuation	Jul-18	Jul-19	Jul-20F	Jul-21F	Jul-22F
Total turnover (MYRm)	420	442	610	683	747
Recurring net profit (MYRm)	17	11	51	59	68
Recurring net profit growth (%)	(31.9)	(36.5)	362.5	15.9	15.6
Recurring P/E (x)	54.17	85.31	18.44	15.92	13.76
P/B (x)	4.6	4.5	3.9	3.3	2.8
P/CF (x)	26.21	24.08	14.90	11.25	9.93
Dividend Yield (%)	1.1	0.7	1.6	1.9	2.2
EV/EBITDA (x)	24.25	29.91	9.44	8.19	7.06
Return on average equity (%)	8.7	5.4	22.6	22.4	22.1
Net debt to equity (%)	21.7	19.1	13.4	6.6	net cash

Note: FY18-19 is annualized. The company change its financial year end to July (from Dec) starting May 2019
Source: Company data, RHB

Note:

Small cap stocks are defined as companies with a market capitalisation of less than USD1bn.

Financial Exhibits

Asia	Financial summary (MYR)	Jul-18	Jul-19	Jul-20F	Jul-21F	Jul-22F
Malaysia	Recurring EPS	0.05	0.03	0.15	0.18	0.21
Consumer Non-cyclical	DPS	0.03	0.02	0.05	0.05	0.06
Daibochi	BVPS	0.62	0.63	0.74	0.86	1.01
DPP MK	Return on average equity (%)	8.7	5.4	22.6	22.4	22.1
Not Rated						
	Valuation metrics	Jul-18	Jul-19	Jul-20F	Jul-21F	Jul-22F
Valuation basis	Recurring P/E (x)	54.17	85.31	18.44	15.92	13.76
P/E	P/B (x)	4.6	4.5	3.9	3.3	2.8
	FCF Yield (%)	3.0	3.1	3.5	4.6	8.5
Key drivers	Dividend Yield (%)	1.1	0.7	1.6	1.9	2.2
i. Ongoing capacity expansion;	EV/EBITDA (x)	24.25	29.91	9.44	8.19	7.06
ii. Securing new big customers.	EV/EBIT (x)	37.24	53.43	12.20	10.48	8.67
Key risks	Income statement (MYRm)	Jul-18	Jul-19	Jul-20F	Jul-21F	Jul-22F
i. Weak consumer spending;	Total turnover	420	442	610	683	747
ii. Sharp fluctuation of raw material prices.	Gross profit	49	45	122	137	149
	EBITDA	41	33	103	118	130
	Depreciation and amortisation	(14)	(14)	(23)	(26)	(24)
	Operating profit	26	18	80	92	106
	Net interest	(4)	(4)	(9)	(10)	(11)
	Pre-tax profit	24	16	71	82	95
	Taxation	(5)	(3)	(18)	(21)	(24)
	Reported net profit	17	11	51	59	68
	Recurring net profit	17	11	51	59	68
Company Profile	Cash flow (MYRm)	Jul-18	Jul-19	Jul-20F	Jul-21F	Jul-22F
Daibochi is a flexible packaging solutions provider in Malaysia and the ASEAN region.	Change in working capital	(5.2)	1.7	(23.1)	(14.3)	(12.7)
	Cash flow from operations	35.6	38.8	62.6	82.9	94.0
	Capex	(7.3)	(9.5)	(30.0)	(40.0)	(15.0)
	Cash flow from investing activities	(25.3)	(19.8)	(30.0)	(40.0)	(15.0)
	Dividends paid	(10.6)	(6.9)	(15.2)	(17.6)	(20.3)
	Cash flow from financing activities	(8.6)	(18.0)	73.2	(2.6)	(11.7)
	Cash at beginning of period	16.7	18.3	18.6	124.4	164.7
	Net change in cash	1.6	0.9	105.8	40.3	67.3
	Ending balance cash	18.9	19.8	124.4	164.7	232.0
	Balance sheet (MYRm)	Jul-18	Jul-19	Jul-20F	Jul-21F	Jul-22F
	Total cash and equivalents	18	19	124	165	232
	Tangible fixed assets	139	139	146	160	151
	Total investments	19	19	19	19	19
	Total assets	366	365	493	567	643
	Short-term debt	53	57	95	90	110
	Total long-term debt	15	5	65	95	95
	Total liabilities	141	135	225	255	280
	Total equity	225	230	268	312	363
	Total liabilities & equity	366	365	493	567	643
	Key metrics	Jul-18	Jul-19	Jul-20F	Jul-21F	Jul-22F
	Revenue growth (%)	10.2	5.4	37.9	11.8	9.4
	Recurrent EPS growth (%)	(32.0)	(36.5)	362.5	15.9	15.6
	Gross margin (%)	11.8	10.1	20.0	20.0	20.0
	Operating EBITDA margin (%)	9.7	7.4	17.0	17.2	17.5
	Net profit margin (%)	4.1	2.5	8.3	8.6	9.1
	Dividend payout ratio (%)	61.4	63.4	30.0	30.0	30.0
	Capex/sales (%)	1.7	2.1	4.9	5.9	2.0
	Interest cover (x)	7.54	4.76	8.61	9.19	9.37

Source: Company data, RHB

Investment Thesis

Best mix of stable earnings – strong clientele base and exposure in F&B

Supported by sustained demand from F&B sector. With 85% of revenue contributed by the F&B sector, we expect Daibochi's revenue base to be more stable during this challenging time. Compared to other sectors, demand from the F&B sector has been less affected by the COVID-19 pandemic. Having several MNCs – Nestle, PepsiCo, Mars and Mondelez International – under its client portfolio also provide stability in terms of product demand and margins. The supply business to MNCs also tends to have higher barriers to entry due to the R&D and relationship-building required before receiving sizable orders.


More cost competitive. With the integration of Scientex, Daibochi now has access to raw materials at more competitive prices, and we have started to see the impact in 1QFY20. For fluctuations in resin prices, the company now has cost pass-through mechanisms for most of its customers (c.85% of sales), which would help to minimise margin fluctuations. However, we note that there could be some time lag before fully passing on the cost. Daibochi may also benefit from lower resin prices – selected customers with whom the company passes on the savings may opt to waive a portion of it. Raw materials account for c.60-65% of the company's cost of sales. Resin prices have been on a declining trend, dropping 17% on average YTD vs 2019's average price – mainly due to lower crude oil prices. Daibochi also recently went through operating efficiency enhancements by streamlining its process with Scientex, which should help to reduce fixed costs and improve operating leverage. The company's EBIT margin improved to 11.6% vs 4.2% in 18MFY19, 9.7% in 2017 and 8.8% in 2016. As such, Daibochi achieved record earnings with only nine months of core earnings in 9MFY20 of MYR37.6m.

Synergistic effect – greater than the sum of its parts

Unlocking value. Daibochi has completed its integration process with Scientex. The two companies now share raw materials procurement, finance and support services, as well as production capabilities. Scientex and Daibochi also will have collaborative R&D and knowledge sharing to further strengthen their competitive advantage. Daibochi is now in the midst of implementing an enhanced production system to MPP's operations – this is expected to have been completed in 3QFY20. Besides increasing its capacity and widening its network of customers and suppliers, the MPP acquisition is also expected to derive synergies from pooling resources, further reducing fixed costs and bulk purchasing of raw materials. Despite having similar products, we expect very little cannibalisation between Daibochi and MPP. MPP focuses more on local customers and this should complement Daibochi that predominantly has multinational clientele. Daibochi's main focus will also be on complex packaging eg multi-layered/special requirements packaging while MPP concentrates on simple packaging structures eg single-layered or bi-laminated structures.

Organic growth to drive future earnings. After all the synergistic benefits kick in, we expect the company's performance to further improve, driven by organic topline expansion and improved operating leverage as it ramps up production. With its strong track record with MNCs, better cost structure, and continuous R&D efforts, we believe the company will strive in securing new clients and new orders from existing clients. Daibochi recently shared that it will be investing MYR60m in capacity expansion, involving the purchase of 13 new lines for printing, lamination and bagging processes to support its long-term growth strategies.

Figure 1: Sales breakdown by sector



Source: Company data

Figure 2: Some of Daibochi's customers



Source: Company data

Valuation and Recommendation

NOT RATED. The fair value of MYR3.85 is derived from 2021F earnings with a target P/E of 20x – in line with the FBMKLCI and 33% premium to peer average. The ascribed 20x target P/E is at +1SD or 19% premium vs its 5-year historical mean (16x). We believe the premium is justified given the company is in the midst of a transformation to unlock its full potential. As mentioned earlier, being part of a much bigger group, the company now should have better access to cheaper raw materials and greater customer reach. Systematic integration with Scientex would help Daibochi enhance its operating efficiency. The recent acquisition of MPP also would help the company to expand capacity and enjoy better economies of scale. The result of these synergies has started to show, with Daibochi's earnings growth, starting 1QFY20.

Historically, the company has always been trading at premium compared to peer average of 15.1x P/E (Figure 3), we believe that this is due to its exposure to MNCs as well as the F&B and fast moving consumer goods (FMCG) sectors, which offer a more stable revenue base. Under the current environment of a lot more uncertainties, stability will be even more appreciated by investors. The market is also anticipating stronger growth from Daibochi in the next two years, compared to peers. Margin wise, we believe Daibochi's PBT margin is slightly better at c.11% compared to the sector average of c.8-9%.

Figure 3: Peer comparison

Company	FYE	Price 17-Aug-20 (MYR)	Mkt Cap (MYRm)	P/E (x)			Div. Yld (%)		ROE (%)		P/BV (x)		EV/ EBITDA		PEG	NP Growth (%)	
				Actual	1-Yr Fwd	2-Yr Fwd	1-Yr Fwd	1-Yr Fwd	1-Yr Fwd	1-Yr Fwd	1-Yr Fwd	1-Yr Fwd	2-Yr Fwd				
Scientex	Jul	9.50	4,901	14.7	13.5	12.0	2.2	15.0	2.0	9.9	1.0	9.0	12.5				
Daibochi	Jul	2.79	913	59.9	18.9	17.0	2.2	23.1	4.2	10.7	1.5	217.9	11.1				
Thong Guan Industries	Dec	5.41	1,007	16.3	13.2	12.1	2.0	12.6	1.6	7.7	1.3	23.0	9.5				
SLP Resources	Dec	1.13	358	16.7	18.8	15.2	4.9	8.2	1.7	9.5	0.6	-11.4	23.6				
SCGM	Apr	3.29	630	36.5	23.6	19.6	1.7	14.9	3.5	12.4	1.0	54.8	20.4				
Tomypak	Dec	0.84	355	-30.6	60.6	40.8	0.2	-0.3	1.8	13.2	0.8	-150.4	48.7				
Market Cap Weighted Avg.			8,480	21.8	15.1	13.3	2.2	15.3	2.3	10.0							


Source: Bloomberg, RHB

Financial Overview

9MFY20 results preview. The company has been showing significant earnings improvement in the past three quarters (Figure 7) as the Scientex-Daibochi integration synergy has started to produce results, aside from the consolidation of MPP's numbers (starting 1QFY20). The group's 9MFY20 core net profit of MYR37.6m has broken its previous record earnings and we expect this to continue, on the back of organic sales growth and margin improvement from the streamlining processes. Note that we will not be able to make YoY earnings comparison as the company has changed its financial year end to July (from December) starting May 2019, to coincide with Scientex.


Daibochi's net gearing stood at a healthy level of 0.23x as at 30 Apr 2020. The company has projected a decent ROE of 23.1%, relatively better compared to peer average ROE of 15.3% (Figure 3).

Figure 4: Sales breakdown by customers' location




Source: Company data

Figure 5: Hitting record earnings in 9MFY20




Source: Company data

Figure 6: Daibochi's quarterly revenue trend



Note: 6Q19* only reported 1 month's number, due to change of financial year.
Note 2: Daibochi started to consolidate MPP's number in 1QFY20.
Source: Company data

Figure 7: Daibochi's core net profit trend



Note: 6Q19* only reported 1 month number, due to change of financial year.
Note 2: Daibochi started to consolidate MPP's number in 1QFY20.
Source: Company data

Key Risks

Key risks for the company include:

- i. **Customers concentration risk.** Based on 19MFY19 revenue, Daibochi's four biggest customers contributed c.46.9% of group revenue. Losing any of this customers would have material impact to its earnings.
- ii. **Unfavourable FX fluctuation.** Given that the company exports some of its product to neighbouring countries within this region and Australia, it has exposure to the AUD, THB and USD. Since Daibochi is net exporter, it will benefit from a weaker MYR. Raw materials sourced are mainly in the MYR.
- iii. **Loss of key management personnel.** The loss of key personnel with extensive knowledge and experience in the business may adversely affect the company's ability to maintain or improve its business performance.
- iv. **Weaker-than-expected consumer sentiment.** The company has high exposure to the consumer sector – significant weakness in consumer demand is detrimental to Daibochi's earnings.
- v. **Steep increase in raw material prices.** The company has a cost pass-through mechanism with most of its customers but there could be some time lag before it can fully pass the cost.

Business Overview

Daibochi is primarily involved in the manufacturing and converting of flexible packaging in the ASEAN region. The company has manufacturing plants in Malaysia and Myanmar as well as sales offices in Thailand, the Philippines and Australia. It supplies to several sectors such as food & beverage, FMCG, pharmaceutical and industrial uses. Daibochi holds several quality and food safety certifications such as ISO:9001, ISO:14001 and FSSC:22000. Its customers include MNCs such as Nestlé, Mondelez International, PepsiCo, Mars, Dutch Lady and Hershey's as well as local companies like Mamee and Power Root (PWRT MK, BUY, TP: MYR2.80).

Figure 8: Packaging solutions offered by Daibochi for various applications

- i. **High Barrier/Performance:** Coffee, Nuts, Potato Chips
- ii. **Cost Effective Barrier:** Snacks, Biscuits, Wafer, Chocolates, Cakes
- iii. **General Packaging:** Outer Pack, Noodles, Biscuits, Wafers
- iv. **Specialty Applications:** Labelling, Ice-Cream, Frozen Food, Cereal Peel Seal, Seasoning Oil, Powder / Liquid Detergent, Shower Foam, Tobacco, Pet Food

Source: Company

Acquisition of MPP. Daibochi proposed to acquire MPP on 3 May 2019, and secured shareholder approval on 11 Jul 2019. This horizontal expansion allows it to widen its product offering and customer reach. Similar to Daibochi, MPP is also primarily involved in the manufacturing of downstream flexible packaging, mainly for F&B applications. The strategy moving forward is to have Daibochi and MPP focus on two different segment of products – Daibochi's main focus will be on complex packaging eg multi-layered/special requirements packaging while MPP concentrates on simple packaging structures eg single-layered or bi-laminated structures. MPP's focus on local customers will also complement Daibochi, which predominantly has multinational clientele.

Figure 9: Top 3 shareholders

Major shareholders	Equity stake
Scientex	61.89%
Apollo Asia Fund	9.38%
Public Mutual	6.37%

Source: Bloomberg

In Feb 2019, Scientex proposed to acquire 42.4% (139m ordinary shares) equity stake in Daibochi for a purchase consideration of MYR22.5m or MYR1.60 per share, which was satisfied through a share swap of 1 new share for every 5.5 Daibochi shares. The offer price of MYR1.60 per share, which implies 20x P/E of Daibochi's FY17 earnings, is slightly above sector valuation. Scientex later increased its stake in Daibochi to 61.89% through a mandatory general offer to Daibochi shareholders, which was ended on 1 Apr 2019.

Recommendation Chart



Source: RHB, Bloomberg

Date	Recommendation	Target Price	Price
2020-08-24			

Source: RHB, Bloomberg

RHB Guide to Investment Ratings

Buy:	Share price may exceed 10% over the next 12 months
Trading Buy:	Share price may exceed 15% over the next 3 months, however longer-term outlook remains uncertain
Neutral:	Share price may fall within the range of +/- 10% over the next 12 months
Take Profit:	Target price has been attained. Look to accumulate at lower levels
Sell:	Share price may fall by more than 10% over the next 12 months
Not Rated:	Stock is not within regular research coverage

Investment Research Disclaimers

RHB has issued this report for information purposes only. This report is intended for circulation amongst RHB and its affiliates' clients generally or such persons as may be deemed eligible by RHB to receive this report and does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this report. This report is not intended, and should not under any circumstances be construed as, an offer or a solicitation of an offer to buy or sell the securities referred to herein or any related financial instruments.

This report may further consist of, whether in whole or in part, summaries, research, compilations, extracts or analysis that has been prepared by RHB's strategic, joint venture and/or business partners. No representation or warranty (express or implied) is given as to the accuracy or completeness of such information and accordingly investors should make their own informed decisions before relying on the same.

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to the applicable laws or regulations. By accepting this report, the recipient hereof (i) represents and warrants that it is lawfully able to receive this document under the laws and regulations of the jurisdiction in which it is located or other applicable laws and (ii) acknowledges and agrees to be bound by the limitations contained herein. Any failure to comply with these limitations may constitute a violation of applicable laws.

All the information contained herein is based upon publicly available information and has been obtained from sources that RHB believes to be reliable and correct at the time of issue of this report. However, such sources have not been independently verified by RHB and/or its affiliates and this report does not purport to contain all information that a prospective investor may require. The opinions expressed herein are RHB's present opinions only and are subject to change without prior notice. RHB is not under any obligation to update or keep current the information and opinions expressed herein or to provide the recipient with access to any additional information. Consequently, RHB does not guarantee, represent or warrant, expressly or impliedly, as to the adequacy, accuracy, reliability, fairness or completeness of the information and opinion contained in this report. Neither RHB (including its officers, directors, associates, connected parties, and/or employees) nor does any of its agents accept any liability for any direct, indirect or consequential losses, loss of profits and/or damages that may arise from the use or reliance of this research report and/or further communications given in relation to this report. Any such responsibility or liability is hereby expressly disclaimed.

Whilst every effort is made to ensure that statement of facts made in this report are accurate, all estimates, projections, forecasts, expressions of opinion and other subjective judgments contained in this report are based on assumptions considered to be reasonable and must not be construed as a representation that the matters referred to therein will occur. Different assumptions by RHB or any other source may yield substantially different results and recommendations contained on one type of research product may differ from recommendations contained in other types of research. The performance of currencies may affect the value of, or income from, the securities or any other financial instruments referenced in this report. Holders of depositary receipts backed by the securities discussed in this report assume currency risk. Past performance is not a guide to future performance. Income from investments may fluctuate. The price or value of the investments to which this report relates, either directly or indirectly, may fall or rise against the interest of investors.

This report does not purport to be comprehensive or to contain all the information that a prospective investor may need in order to make an investment decision. The recipient of this report is making its own independent assessment and decisions regarding any securities or financial instruments referenced herein. Any investment discussed or recommended in this report may be unsuitable for an investor depending on the investor's specific investment objectives and financial position. The material in this report is general information intended for recipients who understand the risks of investing in financial instruments. This report does not take into account whether an investment or course of action and any associated risks are suitable for the recipient. Any recommendations contained in this report must therefore not be relied upon as investment advice based on the recipient's personal circumstances. Investors should make their own independent evaluation of the information contained herein, consider their own investment objective, financial situation and particular needs and seek their own financial, business, legal, tax and other advice regarding the appropriateness of investing in any securities or the investment strategies discussed or recommended in this report.

This report may contain forward-looking statements which are often but not always identified by the use of words such as "believe", "estimate", "intend" and "expect" and statements that an event or result "may", "will" or "might" occur or be achieved and other similar expressions. Such forward-looking statements are based on assumptions made and information currently available to RHB and are subject to known and

unknown risks, uncertainties and other factors which may cause the actual results, performance or achievement to be materially different from any future results, performance or achievement, expressed or implied by such forward-looking statements. Caution should be taken with respect to such statements and recipients of this report should not place undue reliance on any such forward-looking statements. RHB expressly disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or circumstances after the date of this publication or to reflect the occurrence of unanticipated events.

The use of any website to access this report electronically is done at the recipient's own risk, and it is the recipient's sole responsibility to take precautions to ensure that it is free from viruses or other items of a destructive nature. This report may also provide the addresses of, or contain hyperlinks to, websites. RHB takes no responsibility for the content contained therein. Such addresses or hyperlinks (including addresses or hyperlinks to RHB own website material) are provided solely for the recipient's convenience. The information and the content of the linked site do not in any way form part of this report. Accessing such website or following such link through the report or RHB website shall be at the recipient's own risk.

This report may contain information obtained from third parties. Third party content providers do not guarantee the accuracy, completeness, timeliness or availability of any information and are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, or for the results obtained from the use of such content. Third party content providers give no express or implied warranties, including, but not limited to, any warranties of merchantability or fitness for a particular purpose or use. Third party content providers shall not be liable for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or profits and opportunity costs) in connection with any use of their content.

The research analysts responsible for the production of this report hereby certifies that the views expressed herein accurately and exclusively reflect his or her personal views and opinions about any and all of the issuers or securities analysed in this report and were prepared independently and autonomously. The research analysts that authored this report are precluded by RHB in all circumstances from trading in the securities or other financial instruments referenced in the report, or from having an interest in the company(ies) that they cover.

The contents of this report is strictly confidential and may not be copied, reproduced, published, distributed, transmitted or passed, in whole or in part, to any other person without the prior express written consent of RHB and/or its affiliates. This report has been delivered to RHB and its affiliates' clients for information purposes only and upon the express understanding that such parties will use it only for the purposes set forth above. By electing to view or accepting a copy of this report, the recipients have agreed that they will not print, copy, videotape, record, hyperlink, download, or otherwise attempt to reproduce or re-transmit (in any form including hard copy or electronic distribution format) the contents of this report. RHB and/or its affiliates accepts no liability whatsoever for the actions of third parties in this respect.

The contents of this report are subject to copyright. Please refer to Restrictions on Distribution below for information regarding the distributors of this report. Recipients must not reproduce or disseminate any content or findings of this report without the express permission of RHB and the distributors.

The securities mentioned in this publication may not be eligible for sale in some states or countries or certain categories of investors. The recipient of this report should have regard to the laws of the recipient's place of domicile when contemplating transactions in the securities or other financial instruments referred to herein. The securities discussed in this report may not have been registered in such jurisdiction. Without prejudice to the foregoing, the recipient is to note that additional disclaimers, warnings or qualifications may apply based on geographical location of the person or entity receiving this report.

The term "RHB" shall denote, where appropriate, the relevant entity distributing or disseminating the report in the particular jurisdiction referenced below, or, in every other case, RHB Investment Bank Berhad and its affiliates, subsidiaries and related companies.

RESTRICTIONS ON DISTRIBUTION

Malaysia

This report is issued and distributed in Malaysia by RHB Investment Bank Berhad ("RHBIB"). The views and opinions in this report are our own as of the date hereof and is subject to change. If the Financial Services and Markets Act of the United Kingdom or the rules of the Financial Conduct Authority apply to a recipient, our obligations owed to such recipient therein are unaffected. RHBIB has no obligation to update its opinion or the information in this report.

Thailand

This report is issued and distributed in the Kingdom of Thailand by RHB Securities (Thailand) PCL, a licensed securities company that is authorised by the Ministry of Finance, regulated by the Securities and Exchange Commission of Thailand and is a member of the Stock Exchange of Thailand. The Thai Institute of Directors Association has disclosed the Corporate Governance Report of Thai Listed Companies made pursuant to the policy of the Securities and Exchange Commission of Thailand. RHB Securities (Thailand) PCL does not endorse, confirm nor certify the result of the Corporate Governance Report of Thai Listed Companies.

Indonesia

This report is issued and distributed in Indonesia by PT RHB Sekuritas Indonesia. This research does not constitute an offering document and it should not be construed as an offer of securities in Indonesia. Any securities offered or sold, directly or indirectly, in Indonesia or to any Indonesian citizen or corporation (wherever located) or to any Indonesian resident in a manner which constitutes a public offering under Indonesian laws and regulations must comply with the prevailing Indonesian laws and regulations.

Singapore

This report is issued and distributed in Singapore by RHB Securities Singapore Pte Ltd which is a holder of a capital markets services licence and an exempt financial adviser regulated by the Monetary Authority of Singapore. RHB Securities Singapore Pte Ltd may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, RHB Securities Singapore Pte Ltd accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact RHB Securities Singapore Pte Ltd in respect of any matter arising from or in connection with the report.

United States

This report was prepared by RHB and is being distributed solely and directly to "major" U.S. institutional investors as defined under, and pursuant to, the requirements of Rule 15a-6 under the U.S. Securities and Exchange Act of 1934, as amended (the "Exchange Act"). Accordingly, access to this report via Bursa Marketplace or any other Electronic Services Provider is not intended for any party other than "major" US institutional investors, nor shall be deemed as solicitation by RHB in any manner. RHB is not registered as a broker-dealer in the United States and does not offer brokerage services to U.S. persons. Any order for the purchase or sale of the securities discussed herein that are listed on Bursa Malaysia Securities Berhad must be placed with and through Auerbach Grayson ("AG"). Any order for the purchase or sale of all other securities discussed herein must be placed with and through such other registered U.S. broker-dealer as appointed by RHB from time to time as required by the Exchange Act Rule 15a-6. This report is confidential and not intended for distribution to, or use by, persons other than the recipient and its employees, agents and advisors, as applicable. Additionally, where research is distributed via Electronic Service Provider, the analysts whose names appear in this report are not registered or qualified as research analysts in the United States and are not associated persons of Auerbach Grayson AG or such other registered U.S. broker-dealer as appointed by RHB from time to time and therefore may not be subject to any applicable restrictions under Financial Industry Regulatory Authority ("FINRA") rules on communications with a subject company, public appearances and personal trading. Investing in any non-U.S. securities or related financial instruments discussed in this research report may present certain risks. The securities of non-U.S. issuers may not be registered with, or be subject to the regulations of, the U.S. Securities and Exchange Commission. Information on non-U.S. securities or related financial instruments may be limited. Foreign companies may not be subject to audit and reporting standards and regulatory requirements comparable to those in the United States. The financial instruments discussed in this report may not be suitable for all investors. Transactions in foreign markets may be subject to regulations that differ from or offer less protection than those in the United States.

DISCLOSURE OF CONFLICTS OF INTEREST

RHB Investment Bank Berhad, its subsidiaries (including its regional offices) and associated companies, ("RHBIB Group") form a diversified financial group, undertaking various investment banking activities which include, amongst others, underwriting, securities trading, market making and corporate finance advisory.

As a result of the same, in the ordinary course of its business, any member of the RHBIB Group, may, from time to time, have business relationships with or hold positions in the securities (including capital market products) or perform and/or solicit investment, advisory or other services from any of the subject company(ies) covered in this research report.

While the RHBIB Group will ensure that there are sufficient information barriers and internal controls in place where necessary, to prevent/manage any conflicts of interest to ensure the independence of this report, investors should also be aware that such conflict of interest may exist in view of the investment banking activities undertaken by the RHBIB Group as mentioned above and should exercise their own judgement before making any investment decisions.

Malaysia

Save as disclosed in the following link [RHB Research conflict disclosures – August 2020](#) and to the best of our knowledge, RHBIB hereby declares that:

- RHBIB does not have a financial interest in the securities or other capital market products of the subject company(ies) covered in this report.
- RHBIB is not a market maker in the securities or capital market products of the subject company(ies) covered in this report.
- None of RHBIB's staff or associated person serve as a director or board member* of the subject company(ies) covered in this report
**For the avoidance of doubt, the confirmation is only limited to the staff of research department*
- RHBIB did not receive compensation for investment banking or corporate finance services from the subject company in the past 12 months.
- RHBIB did not receive compensation or benefit (including gift and special cost arrangement e.g. company/issuer-sponsored and paid trip) in relation to the production of this report.

Thailand

Save as disclosed in the following link [RHB Research conflict disclosures – August 2020](#) and to the best of our knowledge, RHB Securities (Thailand) PCL hereby declares that:

- RHB Securities (Thailand) PCL does not have a financial interest in the securities or other capital market products of the subject company(ies) covered in this report.
- RHB Securities (Thailand) PCL is not a market maker in the securities or capital market products of the subject company(ies) covered in this report.
- None of RHB Securities (Thailand) PCL's staff or associated person serve as a director or board member* of the subject company(ies) covered in this report
**For the avoidance of doubt, the confirmation is only limited to the staff of research department*
- RHB Securities (Thailand) PCL did not receive compensation for investment banking or corporate finance services from the subject company in the past 12 months.
- RHB Securities (Thailand) PCL did not receive compensation or benefit (including gift and special cost arrangement e.g. company/issuer-sponsored and paid trip) in relation to the production of this report.

Indonesia

Save as disclosed in the following link [RHB Research conflict disclosures – August 2020](#) and to the best of our knowledge, PT RHB Sekuritas Indonesia hereby declares that:

- PT RHB Sekuritas Indonesia and its investment analysts, does not have any interest in the securities of the subject company(ies) covered in this report.
For the avoidance of doubt, interest in securities include the following:
 - Holding directly or indirectly, individually or jointly own/hold securities or entitled for dividends, interest or proceeds from the sale or exercise of the subject company's securities covered in this report*;
 - Being bound by an agreement to purchase securities or has the right to transfer the securities or has the right to pre subscribe the securities*.
 - Being bound or required to buy the remaining securities that are not subscribed/placed out pursuant to an Initial Public Offering*.
 - Managing or jointly with other parties managing such parties as referred to in (a), (b) or (c) above.
- PT RHB Sekuritas Indonesia is not a market maker in the securities or capital market products of the subject company(ies) covered in this report.
- None of PT RHB Sekuritas Indonesia's staff** or associated person serve as a director or board member* of the subject company(ies) covered in this report.
- PT RHB Sekuritas Indonesia did not receive compensation for investment banking or corporate finance services from the subject company in the past 12 months.
- PT RHB Sekuritas Indonesia** did not receive compensation or benefit (including gift and special cost arrangement e.g. company/issuer-sponsored and paid trip) in relation to the production of this report:

Notes:

*The overall disclosure is limited to information pertaining to PT RHB Sekuritas Indonesia only.

**The disclosure is limited to Research staff of PT RHB Sekuritas Indonesia only.

Singapore

Save as disclosed in the following link [RHB Research conflict disclosures – August 2020](#) and to the best of our knowledge, RHB Securities Singapore Pte Ltd hereby declares that:

- RHB Securities Singapore Pte Ltd, its subsidiaries and/or associated companies do not make a market in any issuer covered in this report.
- RHB Securities Singapore Pte Ltd, its subsidiaries and/or its associated companies and its analysts do not have a financial interest (including a shareholding of 1% or more) in the issuer covered in this report.
- RHB Securities, its staff or connected persons do not serve on the board or trustee positions of the issuer covered in this report.
- RHB Securities Singapore Pte Ltd, its subsidiaries and/or its associated companies do not have and have not within the last 12 months had any corporate finance advisory relationship with the issuer covered in this report or any other relationship that may create a potential conflict of interest.
- RHB Securities Singapore Pte Ltd, or person associated or connected to it do not have any interest in the acquisition or disposal of, the securities, specified securities based derivatives contracts or units in a collective investment scheme covered in this report.
- RHB Securities Singapore Pte Ltd and its analysts do not receive any compensation or benefit in connection with the production of this research report or recommendation.

Analyst Certification

The analyst(s) who prepared this report, and their associates hereby, certify that: (1) they do not have any financial interest in the securities or other capital market products of the subject companies mentioned in this report, except for:

Analyst	Company
-	-

(2) no part of his or her compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this report.



KUALA LUMPUR

RHB Investment Bank Bhd
Level 3A, Tower One, RHB Centre
Jalan Tun Razak
Kuala Lumpur 50400
Malaysia
Tel : +603 9280 8888
Fax : +603 9200 2216

JAKARTA

PT RHB Sekuritas Indonesia
Revenue Tower, 11th Floor, District 8 - SCBD
Jl. Jendral Sudirman Kav 52-53
Jakarta 12190
Indonesia
Tel : +6221 509 39 888
Fax : +6221 509 39 777

BANGKOK

RHB Securities (Thailand) PCL
10th Floor, Sathorn Square Office Tower
98, North Sathorn Road, Silom
Bangrak, Bangkok 10500
Thailand
Tel: +66 2088 9999
Fax :+66 2088 9799

SINGAPORE

RHB Securities Singapore Pte Ltd.
10 Collyer Quay
#09-08 Ocean Financial Centre
Singapore 049315
Tel : +65 6533 1818
Fax : +65 6532 6211